At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
BIBW 2948 BS +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of a 4-week Treatment of 15 and 30 mg b.i.d BIBW2948 BS (Inhalation Powder, Hard Capsule for HandiHaler®) on Epithelial Mucin Stores and the Safety and Efficacy in COPD Patients With Symptoms Associated With Chronic Bronchitis
In Brief
A Phase 2 clinical trial evaluating BIBW 2948 BS and Placebo for Pulmonary Disease, Chronic Obstructive and Bronchitis, Chronic. Completed, enrolled 48 participants across 6 sites in 2 countries.
Detailed Summary
Study of BIBW 2948 BS in Patients with COPD and Chronic Bronchitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedJan 2007
Primary CompletionJul 2008
TodayJul 2026
First PostedJan 18, 2007
Enrollment StartJan 17, 2007
Primary CompletionJul 9, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.5 years ago
Interventions
BIBW 2948 BSdrug
Capsule
Placebodrug
Capsule